Industry Supported Sessions

SPONSORED PARALLEL SESSION 01

OLIGOARTICULAR PSA: HOW SHOULD WE APPROACH IT

PROPERLY?

FRIDAY, 15 MARCH

12:40-13:10 AUDITORIUM

Industry session supported by Celgene

Speaker: Maria Sole Chimenti, Italy

 

SPONSORED PARALLEL SESSION 02

ROLE AND CLINICAL DATA OF IXEKIZUMAB IN PSA

FRIDAY, 15 MARCH

12:40-13:10 SALA VERDE

Industry session supported by Eli Lilly

Chair: Salvatore D'Angelo, Italy

Speaker: Luca Idolazzi, Italy

12:40-13:05 Presentation- Role and clinical data of ixekizumab in PSA

13:05-13:10 Discussion

 

SPONSORED PLENARY SESSION 03

UNCONTROLLED SLE – WHEN DO I ADD BELIMUMAB TO

STANDARD THERAPY?

FRIDAY, 15 MARCH

13:25-14:25 SALA VERDE

Industry session supported by GSK

Chair: Ricard Cervera, Spain

13:25 Introduction: Welcome presentation

Ricard Cervera, Spain

13:30 Data presentation: Clinical trial data and real-world evidence for

belimumab in SLE

Roger Levy, USA

FACULTY DISCUSSION

Illustrated with case studies and moderated by Ricard Cervera, Spain

13:40 When to add belimumab before considering another

standard therapy

Luca Iaccarino, Italy

14:00 When to add another standard therapy before considering

belimumab

Giacomo Emmi, Italy

14:20 Conclusion: Closing remarks

Ricard Cervera, Spain

 

SPONSORED PLENARY SESSION 04

RA IN REAL LIFE: WHY BARICITINIB?

SATURDAY, 16 MARCH

09:45-10:15 SALA VERDE

Industry session supported by Eli Lilly

Chair: Bruno Frediani, Italy

Speaker: Luca Quartuccio, Italy

09:45-10:10 Presentation- RA IN REAL LIFE: WHY BARICITINIB?

10:10-10:15 Discussion

 

SPONSORED PLENARY SESSION 05

THE REVOLUTIONARY NOVEL APPLICATIONS OF HIGH

DILUTED BIOLOGICS

SATURDAY, 16 MARCH

13:40-14:40 AUDITORIUM

Industry session supported by Materia Medica

Chairs: Oleg Epstein, Russia

Elena Andrianova, Russia

Aleksandr Kovalchuk, Russia

Speakers: Sergey Tarasov, Russia

Alexander Kovalchuk, Russia

Judith Klein-Seetharaman, USA